临床试验/NCT02038478

NCT02038478撤回2 期

Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Thalassemia

University of Texas Southwestern Medical Center2 个研究点分布在 1 个国家开始时间: 2014年1月最近更新: 2021年7月29日

适应症

试验速览

阶段: 2 期
状态: 撤回
发起方: University of Texas Southwestern Medical Center
试验地点: 2
主要终点: Treatment Success at One Year

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The design of the study incorporates the following features:

This is a phase II study to determine the safety and therapeutic potential of a new transplant approach (disease-free survival, graft versus myeloma effect) and to evaluate its toxicity profile (immediate toxicity, graft-versus-host disease, graft rejection, mortality) in a patient population with severe congenital anemias.
The patient cohort to be studied: Those patients with severe sickle cell disease and thalassemia who have risk factors for high mortality and morbidity related to their disease
Transplant Conditioning Regimen - Immunosuppression without myeloablation: Patients will receive conditioning sufficient to allow donor lympho-hematopoietic engraftment without complete marrow ablation. If the graft is rejected, the patient will reconstitute autologous marrow function. We will use a combination of low dose irradiation, Alemtuzumab (Campath®), and sirolimus.
Peripheral blood hematopoietic progenitor cell (PBPC) transplant: An unmanipulated peripheral blood stem cell collection from a filgrastim (G-CSF) stimulated HLA-matched donor should improve the chance of engraftment because of the high stem cell dose (5 x 106/kg CD34+ cells) and the presence of donor lymphocytes. To reduce the risk of GVHD, patients will receive sirolimus before and after the transplant. The sirolimus will be tapered as necessary to minimize any graft versus host disease while still maintaining adequate chimerism.

详细描述

A human lymphocyte antigen (HLA)-matched sibling donor will receive filgrastim (G-CSF) 10 to16 µg/kg/d subcutaneously or intravenously for up to 6 days with apheresis collections of PBPC on day 5 (and day 6 if required). The product will be collected by leukophoresis with a goal of ≥ 10 x 106 CD34+ cells/kg, with a minimum of 5 x 106 CD34+ cells/kg.

The patient will receive a preparative regimen of Alemtuzumab to be infused on days -7 to -3, followed by 300 cGy TBI given as a single dose on day -2. Sirolimus at a dose of 5mg/day to maintain trough levels between 10-15ng/ml will be started on day -1. The PBPC graft targeted to deliver 10 x 106 CD34+ cells/kg (at minimum, 5 x 106 CD34+ cells/kg) will be infused on day 0 On days +14, +30, +60 and +100 the chimeric status of patients will be assessed by microsatellite analysis of the peripheral blood. More frequent monitoring may be required.

Sickle cell patients with pulmonary hypertension will meet with a Pulmonary Medicine Consult to determine appropriate management prior to SCT.

Patients with fever or suspected minor infection should await resolution of symptoms before starting the conditioning regimen.

Iron chelation must be discontinued > 48 hours before initiating the conditioning regimen.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 45 Years（Adult）
性别: All
接受健康志愿者: 否

入选标准

•Inclusion criteria - Recipient
•Disease specific:
•Sickle Cell Disease - Patients with sickle cell disease at high risk for disease related morbidity or mortality, defined by having irreversible end-organ damage (A, B, C,D, or E) or potentially reversible complication(s) not ameliorated by hydroxyurea (F):
•A. Stroke defined as a clinically significant neurologic event that is accompanied by an infarct on cerebral MRI OR an abnormal trans-cranial Doppler examination (≥200m/s); OR
•B. Sickle cell related renal insufficiency defined by a creatinine level ≥1.5 times the upper limit of normal and kidney biopsy consistent with sickle cell nephropathy OR nephrotic syndrome OR creatinine clearance < 50mL/min OR requiring peritoneal or hemodialysis. OR
•C. Pulmonary hypertension as defined by tricuspid regurgitant jet velocity (TRV) of ≥ 2.5m/s at least 3 weeks after a vaso-occlusive crisis; OR
•D. Recurrent tricorporal priapism defined as at least two episodes of an erection lasting ≥4 hours involving the corpora cavernosa and corpus spongiosa; OR
•E. Sickle hepatopathy defined as EITHER ferritin >1000mcg/L OR direct bilirubin >0.4 mg/dL at baseline; OR
•F. Any one of the below complications
•Vaso-occlusive crises
•Acute chest syndrome
•Osteonecrosis of 2 or more joints
•Red cell alloimmunization
•Thalassemia - Patients with thalassemia who have grade 2 or 3 iron overload, determined by the presence of 2 or more of the following:
•portal fibrosis by liver biopsy inadequate chelation history (defined as failure to maintain adequate compliance with chelation with desferroxamine initiated within 18 months of the first transfusion and administered subcutaneously for 8-10 hours at least 5 days each week) hepatomegaly of greater than 2 cm below the costochondral margin
•Non-disease specific:
•Ages ≥ 18 but ≤ 45
•6/6 HLA matched family donor available
•Ability to comprehend and willing to sign an informed consent, assent obtained from minors
•Negative serum pregnancy test
•Inclusion criteria - Donor
•6/6 HLA identical family donor
•Weight > 20 kg (in so far that the weight difference between recipient and donor does not exceed a reasonable likelihood of being able to obtain an adequate cell dose from the donor within two aphereses)
•Fit to receive G-CSF and give peripheral blood stem cells (normal blood counts, normotensive, and no history of stroke)
•Ability to comprehend and willing to sign an informed consent

排除标准

•Exclusion criteria - Recipient
•Any of the following would exclude the subject from participating
•ECOG performance status of 3 or more or Lanksy performance status of <40
•Diffusion capacity of carbon monoxide (DLCO) <50% predicted (corrected for hemoglobin and alveolar volume)
•Baseline oxygen saturation of <85% or PaO2 <70
•Left ventricular ejection fraction: <40% estimated by ECHO
•Transaminases > 5x upper limit of normal for age
•Evidence of uncontrolled bacterial, viral, or fungal infections (currently taking medication and progression of clinical symptoms) within one month prior to starting the conditioning regimen
•Major anticipated illness or organ failure incompatible with survival from PBSC transplant
•Pregnant or lactating
•Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
•A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
•Has not undergone a hysterectomy or bilateral oophorectomy; or
•Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
•Major ABO mismatch
•Exclusion criteria - Donor
•Any of the following would exclude the donor from participating
•Pregnant or lactating
•Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
•A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
•Has not undergone a hysterectomy or bilateral oophorectomy; or
•Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
•HIV positive
•Hemoglobin S > 50%, or beta thalassemia intermediate

结局指标

主要结局

Treatment Success at One Year

时间窗: Treatment Success at one year

This is defined as full donor type hemoglobin on hemoglobin electrrophoresis for patients with sickle cell disease and transfusion-independence for patients with thalassemia.

次要结局

Level of chierism required to maintain Graft Survival and hematologic normalcy(Measured on days 14, 30, 60 and 100)

研究者

发起方

University of Texas Southwestern Medical Center

申办方类型

Other

责任方

Principal Investigator

主要研究者

Prapti Patel

University of Texas Southwestern Medical Center

研究点 (2)

Loading locations...

相似试验

终止

2 期

Study of Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Hematopoietic Malignancies Including Those That Are Challenging to EngraftHematopoietic Malignancies

NCT03187756NYU Langone Health6

终止

1 期

Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)Lupus ErythematosusGraft-versus-host Disease

NCT02080195Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1

已完成

2 期

Cytokine Induced Killer (CIK) Cells In Leukemia PatientsHematologic Malignancies

NCT01186809A.O. Ospedale Papa Giovanni XXIII74

已完成

2 期

Treosulfan-based Conditioning in Paediatric Patients With Haematological MalignanciesAcute Lymphoblastic Leukaemias (ALL)Acute Myeloid Leukaemias (AML)Myelodysplastic Syndromes (MDS)Juvenile Myelomonocytic Leukaemias (JMML)

NCT02333058medac GmbH70

已完成

2 期

NCT00045435Fred Hutchinson Cancer Center17